# Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease

> **NCT03495973** · — · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 114 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT03495973
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2020-11-22
- **Final completion:** 2020-11-22
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495973, "Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT03495973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*